Bio-Path (BPTH) Sets New 52-Week Low at $0.22

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares hit a new 52-week low during trading on Monday . The stock traded as low as $0.22 and last traded at $0.26, with a volume of 2230800 shares traded. The stock had previously closed at $0.28.

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $1.50 target price (down from $4.50) on shares of Bio-Path in a report on Monday, November 13th. reduced their target price on Bio-Path from $4.50 to $1.50 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Finally, ValuEngine downgraded Bio-Path from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Bio-Path presently has a consensus rating of “Hold” and a consensus target price of $1.67.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, November 9th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). research analysts forecast that Bio-Path Holdings, Inc. will post -0.08 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of BPTH. Bank of New York Mellon Corp lifted its holdings in Bio-Path by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares in the last quarter. Legal & General Group Plc lifted its holdings in Bio-Path by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares in the last quarter. HighTower Advisors LLC lifted its holdings in Bio-Path by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after buying an additional 4,000 shares in the last quarter. Finally, Sabby Management LLC lifted its holdings in Bio-Path by 73.2% during the 2nd quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after buying an additional 503,488 shares in the last quarter. 9.55% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Bio-Path (BPTH) Sets New 52-Week Low at $0.22” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/04/bio-path-bpth-sets-new-52-week-low-at-0-22.html.

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

What are top analysts saying about Bio-Path Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bio-Path Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit